Nideolo (Dimethyl Fumarate)

Dimethyl fumarate, the active ingredient in Nideolo, is an immunomodulating agent presented as an oral formulation for oral use. It is indicated for the treatment of relapsing‑remitting multiple sclerosis and plaque psoriasis in adult patients. GNH USA supplies Nideolo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Dimethyl fumarate acts on immune pathways to modify disease activity in multiple sclerosis and psoriasis. - Relapsing‑remitting multiple sclerosis: reduces the frequency of clinical relapses and slows disability progression. - Plaque psoriasis: improves skin lesions and decreases disease severity.

Dimethyl fumarate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Flushing: transient warmth and redness, often on the face. - Gastrointestinal discomfort: nausea, abdominal pain, or diarrhea. - Lymphopenia: mild reduction in white‑blood‑cell count. - Upper respiratory tract infections: mild cold‑like symptoms.

Serious or Rare Side Effects: - Progressive multifocal leukoencephalopathy (PML): a rare brain infection. - Severe infections: opportunistic infections requiring medical attention. - Hepatic injury: signs of liver dysfunction such as jaundice.

When prescribing Dimethyl fumarate, clinicians should consider several safety measures. - Monitor lymphocyte counts: regular blood tests to detect lymphopenia. - Assess liver function: baseline and periodic liver enzyme testing. - Avoid use in active infections: defer treatment until infection resolves. - Counsel patients on flushing: advise on temperature control and possible dose timing. - Pregnancy considerations: use only if potential benefit justifies potential risk. - Store at room temperature: keep in the original pack, protect from moisture.

Dimethyl fumarate can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Live attenuated vaccines: increased risk of vaccine‑derived infection. - Other immunosuppressants: heightened susceptibility to infections. - Strong CYP inducers: may reduce drug exposure.

Moderate Interactions (Monitor Closely): - Antacids: may affect gastrointestinal absorption. - Concurrent disease‑modifying therapies for MS: overlapping immunomodulation. - NSAIDs: may exacerbate gastrointestinal discomfort.